This cell line has been engineered for use with the CRISPR Synergistic Activation Mediator (SAM) system to induce transcriptional activation and expression of any gene of interest. Cells stably express a mutated dCas9 (Streptococcus pyogenes CRISPR associated protein 9), lacking any endonuclease activity, fused to VP64, a transcriptional activator. Stable dCas9-VP64 expression is maintained with Blasticidin resistance. Cells also stably express P65 (Transcription Factor p65, or Nuclear Factor NF-kappaB p65) and HSF1 (Heat Shock Factor 1) fused with an MS2 tag, which is maintained with Hygromycin resistance. When these cells are transfected with an MS2- tagged sgRNA targeting the promoter region of the gene of interest, dCas9-VP64 and MS2-P65-HSF1 are recruited to the site in the genomic DNA and begin transcription, inducing expression of the desired gene.
Mycoplasma testing: This cell line has been screened using the MycoAlert Mycoplasma Detection Kit (Lonza, #LT07-118) to confirm the absence of Mycoplasma contamination. MycoAlert Assay Control Set (Lonza, #LT07-518) was used as a positive control.
Host Species: human
Supplied as Each vial contains 2 x 106 cells in 1 ml of 10% DMSO.
Host Cell
HepG2
Shipping Temperature
-80°C (dry ice)
Note
The CRISPR/CAS9 technology is covered under numerous patents, including U.S. Patent Nos. 8,697,359 and 8,771,945, as well as corresponding foreign patents applications, and patent rights.License Disclosure: Visit Biohippobioscience.com/license for the label license and other key information about this product.Troubleshooting Guide: Visit Biohippobioscience.com/lentivirus-faq for detailed troubleshooting instructions. For all further questions, please email [email protected]. Warning: Avoid freeze/thaw cycles.
Storage Stability
Cells will arrive upon dry ice and should immediately be thawed or stored in liquid nitrogen upon receipt.
Reference
Konermann, S., et al. Genome-scale transcriptional activation by an engineered CRISPR-Cas9 complex. Nature. 2015. 517(7536): 583-588.